Radiolabeled CCK/gastrin peptides for imaging and therapy of CCK2 receptor-expressing tumors
Related Experiment Video
Updated: Jun 15, 2026
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Susan Roosenburg1, Peter Laverman, Floris L van Delft
1Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. s.ameijde@nucmed.umcn.nl
Abstract:
Cholecystokinin (CCK) receptors are overexpressed in numerous human cancers, like medullary thyroid carcinomas, small cell lung cancers and stromal ovarian cancers. The specific receptor-binding property of the endogenous ligands for these receptors can be exploited by labeling peptides with a radionuclide and using these as carriers to guide the radioactivity to the tissues that express the receptors. In this way, tumors can be visualized using positron emission tomography and single photon emission computed tomography imaging. A variety of radiolabeled CCK/gastrin-related peptides has been synthesized and characterized for imaging. All peptides have the C-terminal CCK receptor-binding tetrapeptide sequence Trp-Met-Asp-Phe-NH(2) in common or derivatives thereof. This review focuses on the development and application of radiolabeled CCK/gastrin peptides for radionuclide imaging and radionuclide therapy of tumors expressing CCK receptors. We discuss both preclinical studies as well as clinical studies with CCK and gastrin peptides.
Insights
Radiolabeled cholecystokinin (CCK) peptides target CCK receptors overexpressed in cancers. These radiolabeled peptides aid in visualizing and potentially treating tumors using advanced imaging and radionuclide therapy.
Area of Science:
- Oncology
- Radiochemistry
- Nuclear Medicine
Background:
- Cholecystokinin (CCK) receptors are frequently overexpressed in various human cancers, including medullary thyroid carcinomas, small cell lung cancers, and stromal ovarian cancers.
- The specific binding properties of CCK ligands can be leveraged for targeted cancer therapies.
Purpose of the Study:
- To review the development and application of radiolabeled CCK/gastrin peptides for imaging and therapy of CCK receptor-expressing tumors.
- To explore the use of these peptides in positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging.
Main Methods:
- Synthesis and characterization of various radiolabeled CCK/gastrin-related peptides.
- Utilizing the common C-terminal CCK receptor-binding tetrapeptide sequence (Trp-Met-Asp-Phe-NH2) or its derivatives.
- Reviewing preclinical and clinical studies involving these radiolabeled peptides.
Main Results:
- Radiolabeled CCK/gastrin peptides demonstrate potential for targeted delivery of radionuclides to tumors.
- These agents can be used for visualizing tumors via PET and SPECT imaging.
- The development of these peptides offers avenues for both diagnostic imaging and therapeutic applications.
Conclusions:
- Radiolabeled CCK/gastrin peptides are promising tools for the diagnosis and treatment of cancers overexpressing CCK receptors.
- Further research and clinical application of these targeted agents are warranted for improved cancer management.
